Page 11 - hypertension_newsletter5_draft2

REFLECTIONS
Hypertension
Hypertension Global Newsletter #5 2023

The authors review and discuss
several post-hoc analyses of RCTs, Hypertension
along with observational studies
in the elderly with frailty, along the
topics of optimal BP targets, risks
of antihypertensive treatments,
deprescribing of antihypertensive
treatments in the elderly, and
challenges of reducing overtreatment
in this patient group. They provide
key considerations for possible
overtreatment of hypertension in older
people with frailty through a suggested
algorithm.

The authors conclude that managing
hypertension in older adults with frailty
is complex due to various health
issues and polypharmacy. This patient
group is likely to have different pharmacokinetics compared to healthy people; therefore, further research specific to this group is
warranted. This study formulates a new paradigm shift of reducing therapy (“deprescribing”) in elderly frail patients, which is a concept
not discussed in previous studies. The ongoing Study on Hypertension and Frailty in Older People (HYPER-FRAIL) is currently
investigating how BP variability interacts with frailty status in older people, while an ongoing UK clinical trial is currently evaluating
the benefits of deprescribing antihypertensive treatments in older people, including those with frailty following the experience of the
OPTIMISE trial. These types of studies will help improve the management of hypertension in this important patient group.

CLICK HERE
FOR THE LINK TO FULL ARTICLE

CLICK HERE
FOR AN INTERESTING COMMENTARY
ARTICLE BY PROF. RIVASI AND
PROF. FEDOROWSKI ON THE HARM
VS. BENEFIT OF ANTIHYPERTENSIVE
TREATMENT IN VERY OLD AND
FRAIL PEOPLE.

TABLE OF CONTENTS